Groundbreaking obesity drug enters human testing phase
NCT ID NCT07238647
Summary
This is the first human study to test the safety of a new experimental drug called HRS-5817 in people with obesity. Researchers will give single injections to 40 participants to see how their bodies handle the drug and check for side effects. The main goal is to determine if the drug is safe enough for further testing, not to measure weight loss in this early phase.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Linear
RECRUITINGPerth, Western Australia, 6027, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.